Real-World HRQOL Findings Support Nivolumab for Previously Treated mRCC
September 19th 2022Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting
Dose-Optimized Regorafenib Provides Comparable, Safe Option for mCRC
September 15th 2022Patients with relapsed or refractory metastatic colorectal cancer who received dose-optimized regorafenib achieved superior survival outcomes than those who received best supportive care, fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil.
Neoadjuvant Nivolumab/Ipilimumab Yields 95% Major Pathological Response Rate in dMMR Colon Cancer
September 13th 2022Neoadjuvant immunotherapy starkly outperformed neoadjuvant chemotherapy in eliciting major pathological responses among patients with mismatch repair–deficient colon cancer, according to investigators.
5-Year Follow-Up Shows Neoadjuvant T-VEC Benefit in Patients with Resectable Melanoma
September 13th 2022The relapse-free survival rate was 22.3% among patients with resectable stage IIIB to IV M1a melanoma who received neoadjuvant talimogene laherparepvec versus 15.2% among those who received surgery alone.
HRQOL Analysis of KEYNOTE-522 Supports Pembrolizumab Treatment for Triple-Negative Breast Cancer
September 12th 2022Patients with triple-negative breast cancer who received pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores compared with patients who received placebo.
Addition of Darolutamide to ADT Shows Comparable Safety Profile Among Patients With nmCRPC
September 16th 2021Patients with nonmetastatic castration-resistant prostate cancer often undergo prolonged treatment periods, making the safety profile of therapies like darolutamide an important factor in optimum treatment selection.
Investigational CAR T-Cell Product Plus Immunotherapy Is Active in DLBCL
September 26th 2020The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Olaparib Significantly Improves PFS in Advanced BRCA+ Ovarian Cancer
November 6th 2018The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) as frontline maintenance therapy in women with BRCA-positive advanced ovarian cancer, according to findings reported at the 2018 European Society of Medical Oncology Congress.
Trial Update Confirms PFS Benefit With Cabozantinib Over Sunitinib in Advanced RCC
September 15th 2017Patients with untreated advanced renal cell carcinoma (RCC) lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent), according to results of an independent review of the randomized CABOSUN trial reported at the 2017 ESMO Congress in Madrid.